Study To Compare Immunogencity Of GSK's Cervical Cancer Candidate Vaccine, Cervarix(r), To Merck's Gardasil(r)

Sun, 21 Jan 2007 04:00 PM EST

... GlaxoSmithKline (NYSE: GSK) has announced the initiation of the first study of its kind designed to compare the immunogenicity of its cervical cancer candidate vaccine, CERVARIX(r), versus Merck's Gardasil(r). The primary objective of the head-to-head trial is to compare the immune responses to HPV types 16 and 18 in U.S. women 18 to 26-years-old. [click link for full article] ...